JBIO

Jade Biosciences, Inc. Common Stock
JBIO
Market cap $218M

6.76 USD

-0.18

2.59%

At close Jun 13, 4:00 PM EDT

1 day

-2.59%

5 days

-16.34%

1 month

-21.49%

3 months

173.68%

6 months

167.19%

Year to date

151.30%

1 year

-72.50%

5 years

-70.39%

10 years

-70.39%

About: Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

4.88% more ownership

Funds ownership: 104.46% [Q4 2024] → 109.34% (+4.88%) [Q1 2025]

3% more funds holding

Funds holding: 80 [Q4 2024] → 82 (+2) [Q1 2025]

0% less capital invested

Capital invested by funds: $79.9M [Q4 2024] → $79.6M (-$382K) [Q1 2025]

52% less call options, than puts

Call options by funds: $76K | Put options by funds: $159K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$17

151%

upside

Avg. target

$17

151%

upside

High target

$17

151%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Wedbush

Laura Chico

151%upside

$17

Outperform

Reiterated

15 May 2025

See Analyst Rankings

Financial journalist opinion

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers expected first-half 2026 to inform patient dose and schedule Company to host conference call and webcast today, June 9, 2025, at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease.

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled “Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN,” will be delivered during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases.

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending March 31, 2025, and provided a corporate update. “The start to 2025 marked a defining period for Jade Biosciences as we successfully completed our reverse merger, commenced trading as JBIO on Nasdaq, and closed a significant private financing led by a premier syndicate of healthcare investors,” said Tom Frohlich, Chief Executive Officer of Jade.

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York. Tom Frohlich , Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m.

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™